Tech problems mar FDA social media event; study finds more orphan drugs at higher prices; Abbott's got milk, lots of it;

@FiercePharma: Top-read on FierceVaccines yesterday: Could soaring vaccine prices spark Sovaldi-style payer pushback? Story | Follow @FiercePharma

@EricPFierce: Weak link in the supply chain. Pharmacist walks out of NY hospital with 1,500 oxycodone tabs. News | Follow @EricPFierce

@CarlyHFierce: Remember that time the NIH found smallpox samples? More | Follow @CarlyHFierce

> The FDA's webinar on social media guidance had technical issues that kept people from being able to participate. Blog post

> Chinese officials say they will "seriously consider" improvements to oversight of manufacturers of active pharmaceutical ingredients. Report

> Abbott Laboratories ($ABT), which sells infant formula like Similac, is partnering with New Zealand's Fonterra Co-Operative Group to invest $300 million in dairy farms in China. Story

> A study by Tufts University says the FDA has approved 86 orphan drugs in the last 14 years but that the costs of many make them too expensive for patients. Story

> The government and payers are sorting out how to share the costs of breakthrough drugs. Story

> The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) told medical professionals not to prescribe an amoxicillin sodium powder made by India's Wockhardt because of reports of injection site reactions. Story

> One of four literature awards made by Merck KGaA for science writing was given to Italian physicist Carlo Rovelli and Mexican physician and writer Francisco Gonzales-Crussi. Release

Medical Device News

@FierceMedDev: Smith & Nephew partners with startup for knee surgical system. More | Follow @FierceMedDev

@StacyALawrence: FDA clears oral sleep apnea device, as search for CPAP alternatives continues. Story | Follow @StacyALawrence

@VarunSaxena2: Cohen: uterine sarcomas often don't cause symptoms; pathology needed for diagnosis, imaging helpful, but not always accurate. | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Article | Follow @MichaelGFierce

@EmilyWFierce: San Francisco gynecologist steps down from FDA panel the day before power morcellator hearings. Story via The Wall Street Journal (sub. req.) | Follow @EmilyWFierce

> ReWalk Robotics marches to market with $58M IPO. Story

> Philips Healthcare chief DiSanzo out in management shakeup. News

> Day One: Inside the FDA power morcelletor panel. Report

> Patent 'troll' legislation passes U.S. House subcommittee with some industry support. Article

Biotech News

@FierceBiotech: EuroBiotech: U.K. pols ready for $PFE's return, $AZN cozies up to EU academia, Israeli biotech upsizes IPO. Report | Follow @FierceBiotech

@JohnCFierce: Parting thought on $SRPT: Stock moves don't tell the whole story, folks. More | Follow @JohnCFierce

@DamianFierce: The "spinversion," a clever new way for companies to cut taxes but spare themselves the fallout of expatriation. Story via Bloomberg | Follow @DamianFierce

@EmilyMFierce: Ongoing Ebola outbreak sparks debate on experimental vaccine testing. Article from FierceVaccines | Follow @EmilyMFierce

> Sanofi's $1.5B dengue vaccine shows Phase III promise, but questions linger. More

> Sage's $60M swing is the next big test of biotech's IPO window. Story

> Ebola outbreak rages on as drug development remains slow. Article

> VC stalwart Sofinnova sets out for a $500M new fund. News

And Finally... UnitedHealth Group says it found the cancer care costs dropped by nearly 35% when doctors were paid a lump sum to treat their patients instead of the traditional pay-for-service method. Story

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.